Overview

Bioequivalence Study of Xian Risperdal Tablets Compared With Gurabo Risperdal Tablets Under Fasting and Fed Conditions in Chinese Healthy Participants

Status:
Withdrawn

Trial end date:
2018-04-27

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to assess the bioequivalence of Xian Risperdal compared with Gurabo Risperdal in Chinese healthy participants under fasting and fed conditions.

Phase:

Phase 1

Details

Lead Sponsor:

Xian-Janssen Pharmaceutical Ltd.

Treatments:

Risperidone